Abstract

Background: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen.

Tags

Monoclonal, Infliximab, Colectomy, Drug Therapy, Ulcerative Colitis, therapeutic use, Treatment Outcome, Antibodies

Read More